Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
NCT ID: NCT01368419
Last Updated: 2013-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
40 participants
INTERVENTIONAL
2011-05-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer
NCT07015489
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
NCT01670409
Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
NCT02745561
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
NCT02375581
Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy
NCT07164690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Endostar
75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
Radiotherapy
6～15MV X-ray, 2Gy/time，5times/week，6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endostar
75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
Radiotherapy
6～15MV X-ray, 2Gy/time，5times/week，6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease according to RECIST criteria
* ECOG Performance Status 0-1
* The length of esophageal carcinoma ≤ 10 cm
* Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L
* Renal function: Cr ≤ 2.0×UNL
* Hepatic function: BIL ≤ 2.0×UNL, ALT/AST ≤ 5.0×UNL
Exclusion Criteria
* Evidence of bleeding diathesis, serious infection
* Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)
* Uncontrollable mental and nervous disorders
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First People's Hospital of Lianyungang
OTHER
Jiangsu Simcere Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaodong Jiang, MD
Role: PRINCIPAL_INVESTIGATOR
The First People's Hospital of Lianyungang
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Xiaodong Jiang, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaodong Jiang, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Endu-201105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.